- Record: found
- Abstract: found
- Article: not found
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
Daniel J Sargent
1 ,
Silvia Marsoni ,
Genevieve Monges ,
Stephen N Thibodeau ,
Roberto Labianca ,
Stanley R Hamilton ,
Amy J French ,
Brian Kabat ,
Nathan R Foster ,
Valter Torri ,
Christine Ribic ,
Axel Grothey ,
Malcolm Moore ,
Alberto Zaniboni ,
Jean-Francois Seitz ,
Frank Sinicrope ,
Steven Gallinger
Jul 10 2010
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Prior reports have indicated that patients with colon cancer who demonstrate high-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have improved survival and receive no benefit from fluorouracil (FU) -based adjuvant therapy compared with patients who have microsatellite-stable or proficient mismatch repair (pMMR) tumors. We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer.